Vincerx Pharma Inc (VINC)
0.8847
+0.06
(+6.98%)
USD |
NASDAQ |
May 01, 16:00
0.8802
0.00 (0.00%)
After-Hours: 20:00
Vincerx Pharma Cash from Investing (TTM): 41.50M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.50M |
| September 30, 2023 | 15.37M |
| June 30, 2023 | -19.89M |
| March 31, 2023 | -34.69M |
| December 31, 2022 | -40.58M |
| September 30, 2022 | -20.20M |
| June 30, 2022 | -0.03M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.258M |
| December 31, 2021 | -5.258M |
| September 30, 2021 | -5.25M |
| June 30, 2021 | -5.228M |
| March 31, 2021 | -5.00M |
| December 31, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-40.58M
Minimum
Dec 2022
41.50M
Maximum
Dec 2023
-6.117M
Average
-5.228M
Median
Jun 2021
Cash from Investing (TTM) Benchmarks
| Trxade Health Inc | -0.2757M |
| MyMD Pharmaceuticals Inc | 1.846M |
| Acrivon Therapeutics Inc | 50.72M |
| Ligand Pharmaceuticals Inc | -11.68M |
| Regulus Therapeutics Inc | 14.49M |